Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$128.05−1.61 (-1.24%)
Close on Nov 16, 2026Market cap $5.35BP/E –Yield –
Veradermics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$111.91.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$111.91 | – |
| FY2024 | Dec 31, 2024 | -$37.05 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.58 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.32 | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.19 | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.79 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?